Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.57 Insider Own34.26% Shs Outstand26.65M Perf Week0.75%
Market Cap463.18M Forward P/E- EPS next Y-2.97 Insider Trans-0.11% Shs Float17.52M Perf Month24.50%
Income-69.42M PEG- EPS next Q-0.69 Inst Own71.82% Short Float3.10% Perf Quarter11.62%
Sales0.00M P/S- EPS this Y76.94% Inst Trans- Short Ratio3.60 Perf Half Y45.68%
Book/sh5.56 P/B3.13 EPS next Y-4.00% ROA-47.71% Short Interest0.54M Perf Year-
Cash/sh7.32 P/C2.37 EPS next 5Y- ROE-58.63% 52W Range9.00 - 22.33 Perf YTD29.51%
Dividend Est.- P/FCF- EPS past 5Y- ROI-36.24% 52W High-22.17% Beta-
Dividend TTM- Quick Ratio9.16 Sales past 5Y19.69% Gross Margin- 52W Low93.11% ATR (14)1.22
Dividend Ex-Date- Current Ratio9.16 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)58.60 Volatility9.57% 7.42%
Employees58 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price22.43
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q-10.67% Payout- Rel Volume0.95 Prev Close18.76
Sales Surprise- EPS Surprise-4.35% Sales Q/Q- EarningsMay 09 BMO Avg Volume150.98K Price17.38
SMA206.98% SMA5022.42% SMA20021.27% Trades Volume143,261 Change-7.36%
Date Action Analyst Rating Change Price Target Change
Jun-13-24Initiated Robert W. Baird Outperform $28
Jun-06-24Initiated H.C. Wainwright Buy $22
Nov-28-23Initiated Stifel Buy $20
Nov-28-23Initiated RBC Capital Mkts Outperform $22
Nov-28-23Initiated Leerink Partners Outperform $19
Nov-28-23Initiated JP Morgan Overweight $20
Nov-28-23Initiated Chardan Capital Markets Buy $23
May-14-24 12:00PM
May-09-24 07:00AM
May-07-24 07:30AM
Apr-22-24 07:30AM
07:30AM Loading…
Apr-16-24 07:30AM
Mar-13-24 04:22PM
Mar-11-24 07:42AM
Feb-05-24 07:00AM
Jan-03-24 07:00AM
Dec-18-23 07:00AM
Dec-13-23 04:59AM
Dec-11-23 12:05PM
08:42AM Loading…
Nov-30-23 08:42AM
Nov-02-23 09:51PM
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Townsend Richard NolanChief Executive OfficerJun 10 '24Option Exercise2.335,00011,650175,695Jun 12 05:00 PM
Townsend Richard NolanChief Executive OfficerJun 10 '24Sale17.655,00088,264170,695Jun 12 05:00 PM
Townsend Richard NolanChief Executive OfficerMay 13 '24Option Exercise2.335,00011,650175,695May 14 04:04 PM
Townsend Richard NolanChief Executive OfficerMay 13 '24Sale13.225,00066,093170,695May 14 04:04 PM
Longitude Capital Partners IV,10% OwnerNov 07 '23Buy11.00454,5454,999,9952,567,100Nov 09 08:32 PM
Omega Fund VI, L.P.10% OwnerNov 07 '23Buy11.00454,5454,999,9952,157,623Nov 09 08:36 PM
Lundbeckfond Invest A/S10% OwnerNov 07 '23Buy11.00227,2722,499,9921,835,959Nov 09 08:33 PM